Skip to main content

Table4 Prognostic factors for overall survival of patient with SCRC

From: Clinicopathologic characteristics and prognosis of synchronous colorectal cancer: a retrospective study

Characteristics

Univariate analysis

Multivariate analysis

HR (95%CI)

P valuea

HR (95%CI)

P valuea

Sex

 Female

1

(Reference)

  

 Male

1.30 (0.79–2.12)

0.305

  

EOCRC or LOCRC

 LOCRC

1

(Reference)

1

(Reference)

 EOCRC

0.55 (0.28–1.11)

0.096

0.28 (0.13–0.62)

0.002

Family history of tumours

 No

1

(Reference)

1

(Reference)

 Yes

0.37 (0.09–1.49)

0.160

0.57 (0.12–2.80)

0.488

BMI (kg/m2)

 18.5 to 24

1

(Reference)

  

 < 18.5

0.97 (0.52–1.83)

0.927

  

 ≥ 24

0.78 (0.47–1.28)

0.320

  

Haemoglobin (g/L)

 > 110

1

(Reference)

1

(Reference)

 ≤ 100

1.80 (1.17–2.77)

0.007

1.75 (1.07–2.84)

0.025

Platelet counts (109/L)

 ≤ 300

1

(Reference)

  

 > 300

1.20 (0.76–1.89)

0.431

  

WBC (109/L)

 ≤ 10

1

(Reference)

  

 > 10

1.19 (0.60–2.38)

0.622

  

CEA (ng/mL)

 ≤ 10

1

(Reference)

1

(Reference)

 > 10

2.65 (1.72–4.09)

< 0.001

1.38 (0.82–2.31)

0.220

CA199 (kU/L)

 ≤ 27

1

(Reference)

1

(Reference)

 > 27

2.24 (1.44–3.47)

< 0.001

1.04 (0.61–1.78)

0.884

CA125 (kU/L)

 ≤ 35

1

(Reference)

1

(Reference)

 > 35

5.88 (3.49–9.91)

< 0.001

4.19 (2.23–7.85)

< 0.001

CA153 (kU/L)

 ≤ 25

1

(Reference)

1

(Reference)

 > 25

5.78 (1.79–18.69)

0.003

3.65 (0.98–13.57)

0.054

AFP (ng/mL)

 ≤ 7

1

(Reference)

  

 > 7

0.68 (0.22–2.16)

0.516

  

Type of ascites

 No

1

(Reference)

1

(Reference)

 Serous

1.28 (0.62–2.66)

0.505

0.55 (0.24–1.24)

0.150

 Bloody

6.78 (2.12–21.74)

0.001

3.53 (0.87–14.27)

0.077

Tumor location

 Right colon

1

(Reference)

  

 Left colon

0.68 (0.35–1.32)

0.257

  

 Rectum

0.77 (0.42–1.41)

0.398

  

 Multiple segment

0.68 (0.38–1.23)

0.200

  

Radical or palliative surgery

 Radical

1

(Reference)

1

(Reference)

 Palliative

6.45 (4.17–9.96)

< 0.001

2.87 (1.17–7.02)

0.021

 (y)pTNM staging

 0–I

1

(Reference)

1

(Reference)

 II

3.13 (0.72–13.6)

0.129

2.77 (0.63–12.22)

0.178

 III

5.32 (1.26–22.53)

0.023

5.34 (1.24–22.98)

0.025

 IV

17.27 (4.18–71.47)

< 0.001

5.89 (1.16–29.77)

0.032

Number of retrieved lymph nodes

 < 12

1

(Reference)

1

(Reference)

 ≥ 12

1.82 (0.94–3.53)

0.075

1.55 (0.75–3.22)

0.240

Gross classification

 Mass type

1

(Reference)

  

 Infiltration type

1.75 (0.53–5.71)

0.355

  

 Ulceration type

0.86 (0.55–1.34)

0.499

  

Histological type

 Classical adenocarcinoma

1

(Reference)

  

 Mucinous adenocarcinoma

0.64 (0.26–1.57)

0.328

  

 Signet ring cell carcinoma

0 (0-Inf)

0.994

  

Differentiation grade

 Well differentiated

1

(Reference)

  

 Moderately differentiated

1.15 (0.65–2.02)

0.634

  

 Poorly differentiated

1.09 (0.53–2.23)

0.824

  

Vessel invasion

 Negative

1

(Reference)

1

(Reference)

 Positive

1.82 (1.11–2.99)

0.018

1.09 (0.60–1.98)

0.780

Neural invasion

 Negative

1

(Reference)

1

(Reference)

 Positive

2.37 (1.45–3.87)

0.001

1.32 (0.71–2.44)

0.378

Ki67 expression

 Low

1

(Reference)

1

(Reference)

 Moderate

0.64 (0.28–1.43)

0.275

1.10 (0.45–2.66)

0.833

 High

0.58 (0.30–1.13)

0.111

1.00 (0.47–2.13)

0.999

MMR status

 pMMR

1

(Reference)

1

(Reference)

 dMMR

0.48 (0.22–1.04)

0.063

0.77 (0.32–1.83)

0.551

  1. HR hazard ratio, CI confidence interval. aThe bolded P value was statistically significant (P < 0.05)